Propanc Biopharma, Inc. Common Stock

Propanc Biopharma is pursuing a strategic initiative to acquire Digital Asset Treasury (DAT) companies trading below their market cap to net asset value, aiming to diversify its asset base and create shareholder value.

Propanc Biopharma secured a strategic financing agreement with Hexstone Capital for up to $100 million, involving convertible preferred stock and warrants to support clinical pipeline development and digital asset treasury strategy.

Propanc Biopharma successfully closed a public offering of 1,000,000 shares at $4.00 per share, raising $4 Million and commencing trading on the Nasdaq Capital Market under the ticker PPCB.

Propanc Biopharma announced a public offering of 1 million shares at $4.00 per share, expecting to raise approximately $4 million. The company will use proceeds for working capital and has received approval to list on Nasdaq Capital Market.